NPC1L1 and cancer: This revealed NPC1L1, the direct target of the clinical hypolipidemic drug ezetimibe, as a key oxidative stress effector expressed highly in MDR persister cancer cells, contributing to enhanced uptake of vitamin E to partially counteract the combinatorial therapy‐induced oxidative stress.